ABSTRACT
BACKGROUND: The Cystic Fibrosis (CF) Foundation recommends patients attend clinic ≥4 times per year with 4 respiratory cultures and 2 pulmonary function tests (PFTs). However, nationally only 57.4% of patients met these guidelines in 2012. We used a quality improvement program with a goal of 75% of our patients meeting this care guideline by 2012. METHODS: A 2-stage program was started in 2011. Stage 1: education of patients/caregivers on importance of quarterly visits. Stage 2: quarterly tracking system of patient appointments. Data on clinic visits, respiratory cultures, and PFTs were collected from the CF registry from January 2009 through December 2013. Statistical process control charts were used to track improvements. RESULTS: The average number of clinic visits increased significantly from 4.6 ± 2.3 in 2009 to 6.3 ± 4.6 in 2013 (P < .0001). The percentage of patients ages 6 through 18 completing a clinic visit, PFT, and respiratory culture per quarter increased significantly from 76.2% during 2009 to 86.4% in 2013. The percentage of patients completing ≥4 clinic visits with 4 respiratory cultures and 2 PFTs improved significantly from 47.5% in 2009 to 71.0% in 2013 (P < .0001). CONCLUSIONS: A tracking system of patient appointments significantly improved adherence to the care guidelines better than education alone. The multiple-stage quality improvement program we implemented may be modifiable and able to be integrated in other CF centers or other multiple disciplinary chronic illness care centers.
Subject(s)
Ambulatory Care/statistics & numerical data , Cystic Fibrosis/therapy , Guideline Adherence/statistics & numerical data , Patient Compliance/statistics & numerical data , Quality Improvement/organization & administration , Adolescent , Ambulatory Care/methods , Ambulatory Care/organization & administration , Appointments and Schedules , Child , Child, Preschool , Cystic Fibrosis/diagnosis , Cystic Fibrosis/microbiology , Female , Follow-Up Studies , Humans , Infant , Infant, Newborn , Male , Patient Education as Topic , Practice Guidelines as Topic , Process Assessment, Health Care , Program Evaluation , Quality Improvement/statistics & numerical data , Respiratory Function Tests/statistics & numerical data , Respiratory System/microbiologyABSTRACT
BACKGROUND: Vancomycin is the drug-of-choice for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in children with cystic fibrosis. However, no studies have characterized the pharmacokinetic profile of vancomycin among pediatric cystic fibrosis patients. OBJECTIVE: To evaluate the pharmacokinetics of intermittent vancomycin administration in children with cystic fibrosis and identify covariates that significantly influence vancomycin efficacy and safety. METHODS: Therapeutic drug monitoring data were obtained from two cystic fibrosis care centers that identified children < 18 years who received vancomycin treatment for an acute pulmonary exacerbation from 2005 to 2010. Trough and peak serum concentrations were determined before and after the third or fourth dose. Nonlinear mixed effects models were developed to evaluate the population pharmacokinetics of vancomycin. RESULTS: Among the 67 children (mean age 12.1 ± 5.3 years), the mean vancomycin dose was 17.4 ± 4.4 mg/kg. The mean trough concentration (Cmin ) was 10.3 ± 3.8 mg/L. The mean daily area under the serum concentration time curve (AUC24 ) was 282.5 ± 816.9 mg·hour/L. A one-compartment model with first-order elimination best described the data. Weight significantly influenced vancomycin clearance (p<0.001). In the final model, clearance was estimated as 5.57 L/hour/70 kg, and the volume of distribution was 44.1 L/70 kg. The between subject variability for clearance and volume of distribution were 27% and 40%, respectively. CONCLUSIONS: Using a one-compartment model to evaluate the pharmacokinetic properties of vancomycin in children with cystic fibrosis, clearance increased with body weight. Pharmacodynamic studies are needed to establish an optimal vancomycin dosing regimen for the treatment of pediatric exacerbations of cystic fibrosis.
Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Cystic Fibrosis/drug therapy , Staphylococcal Infections/drug therapy , Vancomycin/pharmacokinetics , Adolescent , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Area Under Curve , Body Weight , Child , Cystic Fibrosis/microbiology , Dose-Response Relationship, Drug , Drug Monitoring , Female , Humans , Male , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Models, Biological , Nonlinear Dynamics , Staphylococcal Infections/microbiology , Tissue Distribution , Vancomycin/administration & dosage , Vancomycin/therapeutic useABSTRACT
Vocal cord dysfunction is characterised by paradoxical vocal cord adduction that occurs during inspiration, resulting in symptoms of dyspnoea, wheeze, chest or throat tightness and cough. Although the condition is well described in children and adults, confusion with asthma often triggers the use of an aggressive treatment regimen directed against asthma. The laryngoscopic demonstration of vocal cord adduction during inspiration has been considered the gold standard for the diagnosis of vocal cord dysfunction, but historical factors and pulmonary function findings may provide adequate clues to the correct diagnosis. Speech therapy, and in some cases psychological counselling, is often beneficial in this disorder. The natural course and prognosis of vocal cord dysfunction are still not well described in adults or children.
Subject(s)
Vocal Cord Paralysis/diagnosis , Vocal Cord Paralysis/etiology , Child , Humans , Vocal Cord Paralysis/therapyABSTRACT
The authors present a case of an 11-year-old boy with a history of mild asthma and cough who underwent radiographic examination of the chest. The radiograph showed a round, discrete mass in the right cardiophrenic angle. The patient underwent thoracoscopic excision, and histologic examination found a unilocular, pericardial cyst. The possible causes of mediastinal masses and an argument for their surgical removal is presented.
